Cullinan Therapeutics, Inc. Balance Sheet
CGEM / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
Cullinan Therapeutics, Inc. had $622M in total assets and $590M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | $83.0M | $98.4M | $156.2M | $59.8M | $168.2M |
| Current Assets | $414.7M | $480.2M | $474.5M | $296.6M | $212.3M |
| PP&E (Net) | $683.0K | $989.0K | $1.2M | $77.0K | $130.0K |
| Total Assets | $621.8M | $484.2M | $561.1M | $437.2M | $214.7M |
| Current Liabilities | $30.6M | $28.1M | $22.5M | $11.7M | $14.3M |
| Shareholders' Equity | $590.3M | $453.7M | $535.0M | $425.0M | $200.3M |